Literature DB >> 20085587

Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Hai-Rim Shin1, Jin-Kyoung Oh, Eric Masuyer, Maria-Paula Curado, Veronique Bouvard, Yue-Yi Fang, Surapon Wiangnon, Banchob Sripa, Sung-Tae Hong.   

Abstract

Cholangiocarcinoma is relatively rare, but high incidence rates have been reported in Eastern Asia, especially in Thailand. The etiology of this cancer of the bile ducts appears to be mostly due to specific infectious agents. In 2009, infections with the liver flukes, Clonorchis sinensis or Opistorchis viverrini, were both classified as carcinogenic to humans by the International Agency for Research on Cancer for cholangiocarcinoma. In addition, a possible association between chronic infection with hepatitis B and C viruses and cholangiocarcinoma was also noted. The meta-analysis of published literature revealed the summary relative risks of infection with liver fluke (both Opistorchis viverrini and Clonorchis sinensis), hepatitis B virus, and hepatitis C virus to be 4.8 (95% confidence interval [95% CI]: 2.8-8.4), 2.6 (95% CI: 1.5-4.6), and 1.8 (95% CI: 1.4-2.4), respectively - liver fluke infection being the strongest risk factor for cholangiocarcinoma. Countries where human liver fluke infection is endemic include China, Korea, Vietnam, Laos, and Cambodia. The number of infected persons with Clonorchis sinensis in China has been estimated at 12.5 million with considerable variations among different regions. A significant regional variation in Opistorchis viverrini prevalence was also noted in Thailand (average 9.6% or 6 million people). The implementation of a more intensive preventive and therapeutic program for liver fluke infection may reduce incidence rates of cholangiocarcinoma in endemic areas. Recently, advances have been made in the diagnosis and management of cholangiocarcinoma. Although progress on cholangiocarcinoma prevention and treatment has been steady, more studies related to classification and risk factors will be helpful to develop an advanced strategy to cure and prevent cholangiocarcinoma.

Entities:  

Mesh:

Year:  2009        PMID: 20085587     DOI: 10.1111/j.1349-7006.2009.01458.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  155 in total

1.  Molecular expression and characterization of a novel protein phosphatase 2A gene from Clonorchis sinensis.

Authors:  Chuanhuan Deng; Xinbing Yu; Xuerong Li; Jiufeng Sun; Lexun Wang; Xiaoyun Wang; Wenjun Chen; Xiaoli Lv; Xuchu Hu; Zhongdao Wu; Chi Liang; Jin Xu
Journal:  Parasitol Res       Date:  2011-12-14       Impact factor: 2.289

Review 2.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

3.  Exceptionally high prevalence of infection of Bithynia siamensis goniomphalos with Opisthorchis viverrini cercariae in different wetlands in Thailand and Lao PDR.

Authors:  Nadda Kiatsopit; Paiboon Sithithaworn; Weerachai Saijuntha; Thidarut Boonmars; Smarn Tesana; Jiraporn Sithithaworn; Trevor N Petney; Ross H Andrews
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

Review 4.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.

Authors:  William C Palmer; Tushar Patel
Journal:  J Hepatol       Date:  2012-03-13       Impact factor: 25.083

Review 5.  Imaging and interventions in hilar cholangiocarcinoma: A review.

Authors:  Kumble Seetharama Madhusudhan; Shivanand Gamanagatti; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2015-02-28

Review 6.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

7.  Milk fat globule epidermal growth factor 8 serves a novel biomarker of opisthorchiasis-associated cholangiocarcinoma.

Authors:  Zhiliang Wu; Thidarut Boonmars; Isao Nagano; Watcharin Loilome; Puangrat Yongvanit; Narong Khuntikeo; Phuangphaka Sadee Nielsen; Chawalit Paorojkul; Yuzo Takahashi; Yoichi Maekawa
Journal:  Tumour Biol       Date:  2014-03

8.  Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.

Authors:  W F Shen; W Zhong; Q Liu; C J Sui; Y Q Huang; J M Yang
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 9.  Obesity and cholangiocarcinoma.

Authors:  Mansour A Parsi
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 10.  The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

Authors:  Hwajeong Lee; Jeffrey S Ross
Journal:  Therap Adv Gastroenterol       Date:  2017-03-28       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.